Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

At a recent event in the Department of Pharmacology, featuring DPhil and MSC students along with early career researchers, the formation of the Oxford Pharmacology Society (OPS) was announced.

The society aims to provide a platform to invite speakers and alumni in the interest of networking and career advice. At an event in November, Dr Sridhar Vasudevan talked to the group about his journey from MSc student to Principal Investigator, including details of his involvement in an academic spinout. The next event, to be held on 16 January 2019, is entitled ‘Beyond academia: The intricate world of intellectual property’ and will be presented by Dr Tanya Heare-Rowlands, a former DPhil student in the Platt lab who is now an IP lawyer. The Society is being run by Dragos Mosneagu in the Vasudevan lab, Carla Santos and Mylene Huebecker in the Platt lab and Arup Nath in the Minichiello group. For full details see http://www.opharmsoc.co.uk – register here for the OPS mailing list. All graduate students and early career researchers welcome.

Similar stories

Modernized Oxford anti-arrhythmic drug classification gains global recognition as the new standard in antiarrhythmic drug clinical guidelines

Cardiac arrhythmias pose a serious global health challenge. The commonest sustained arrhythmia atrial fibrillation (AF) affects 1–2% of the worldwide population. Antiarrhythmic drugs (AADs) remain central to their pharmacotherapeutic management. As a solution, Professors Ming Lei, Derek Terrar (both Pharmacology), Christopher Huang (University of Cambridge), and Lin Wu (Beijing University Hospital) developed and proposed the 2018 Oxford modernized antiarrhythmic drug (AAD) classification (Circulation, 2018;138:1879–1896).